Literature DB >> 16977968

[Prevalence of antinuclear envelope antibodies and their isotypes in sera positive for antinuclear antibodies].

Miriam Arcavi1, Gladys Orfus.   

Abstract

Antinuclear antibodies detected in HEp-2 cells by indirect immunofluorescence assay display a great variety of images, including the nuclear envelope pattern. This is quite a less frequent finding. Two thousand five hundred and ninety-four sera were processed, and 37.6% of ANA were detected. The prevalence of anti-nuclear envelope antibodies (ANEA) was of 1.2%, with a high association with autoimmune liver diseases (83%) and a low association with systemic lupus erythematosus. In 21 sera of patients with ANEA, no anti-DNAn antibodies were found; but 28.6% of anti-smooth muscle antibodies and 19% of anti-mitochondrial antibodies were detected. The triple rodent tissue section proved to be a less sensitive substrate than HEp-2 for the detection of ANEA. When using conjugates against different isotypes of antibodies for the detection of ANA, 90.5% of IgG, 66.6% of IgA and 9.5% of IgM. Two patients had ANEA-IgA at high titers (> or = 1:160) without ANEA-IgG. In this work, the importance of performing complementary tests for the detection of anti-smooth muscle antibodies, anti-mitochondrial antibodies and anti-DNAn is highlighted in order to apply these tests as guidelines for the clinical diagnosis of patients with ANEA. Besides, this study expresses the need of using total anti-Ig antibodies as conjugate for IIF-HEp-2 instead of anti-lgG; until the role of IgA antibodies in these autoimmune diseases is clarified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16977968

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  1 in total

1.  High frequency of Smith autoantibodies in Omani patients with systemic lupus erythematosus.

Authors:  Ali A Al-Jabri; Amal K Al-Gahdani; Ibtisam Al-Shuaili
Journal:  Rheumatol Int       Date:  2009-11       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.